Attached files
| file | filename |
|---|---|
| 8-K - FORM 8-K - WebMD Health Corp. | d305924d8k.htm |
| EX-99.4 - EX-99.4 - WebMD Health Corp. | d305924dex994.htm |
| EX-99.2 - EX-99.2 - WebMD Health Corp. | d305924dex992.htm |
| EX-99.1 - EX-99.1 - WebMD Health Corp. | d305924dex991.htm |
Exhibit 99.3
WebMD Health Corp.
Financial Guidance for the Year Ending December 31, 2012
(in millions, except per share amounts)
| Year Ending December 31, 2012 Guidance Range |
||||||||
| Revenue |
$ | 500.0 | $ | 535.0 | ||||
|
|
|
|
|
|||||
| Earnings before interest, taxes, depreciation, amortization |
$ | 100.0 | $ | 125.0 | ||||
| Interest, taxes, depreciation, amortization and other non-cash items (b) |
||||||||
| Interest expense, net |
(23.0 | ) | (23.0 | ) | ||||
| Depreciation and amortization |
(28.0 | ) | (27.0 | ) | ||||
| Non-cash stock-based compensation |
(48.0 | ) | (46.0 | ) | ||||
| Severance & other expense |
(1.0 | ) | (1.0 | ) | ||||
|
|
|
|
|
|||||
| Pre-tax income from continuing operations |
— | 28.0 | ||||||
| Income tax provision |
(2.0 | ) | (13.0 | ) | ||||
|
|
|
|
|
|||||
| (Loss) income from continuing operations |
$ | (2.0 | ) | $ | 15.0 | |||
|
|
|
|
|
|||||
| (Loss) income from continuing operations per share: |
||||||||
| Basic |
$ | (0.04 | ) | $ | 0.26 | |||
|
|
|
|
|
|||||
| Diluted |
$ | (0.04 | ) | $ | 0.26 | |||
|
|
|
|
|
|||||
| Weighted-average shares outstanding used in computing per share amounts: |
||||||||
| Basic |
57.0 | 57.0 | ||||||
|
|
|
|
|
|||||
| Diluted |
57.0 | 58.0 | ||||||
|
|
|
|
|
|||||
| (a) | See Annex A - Explanation of Non-GAAP Financial Measures |
| (b) | Reconciliation of Adjusted EBITDA to income from continuing operations |
Additional information regarding forecast for the quarter ending March 31, 2012:
| • | Revenue is forecasted to be in excess of $105 million. |
| • | Adjusted EBITDA as a percentage of revenue is forecasted to be approximately 10% to 11%. |
| • | Loss from continuing operations as a percentage of revenue is forecasted to be approximately 9% to 13%. |
| • | Loss from continuing operations includes pre-tax stock-based compensation expense of approximately $8 million related to the surrender of certain stock options by WebMD’s directors and executive officers. |
Additional information regarding full year forecast:
| • | The distribution of the annual revenue is expected to be approximately 84% public portals advertising and sponsorship and 16% private portal licensing. Quarterly revenue distributions may vary from this annual estimate. |
| • | 2012 guidance excludes any gains or losses related to investments or convertible notes. |
| • | Convertible notes are not expected to be dilutive for the full year or any quarter. |